Media stories about Syndax Pharmaceuticals (NASDAQ:SNDX) have trended somewhat positive on Thursday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6840090731017 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) traded down $0.05 during trading on Thursday, reaching $8.55. 317,100 shares of the company’s stock were exchanged, compared to its average volume of 160,519. Syndax Pharmaceuticals has a 1 year low of $6.31 and a 1 year high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.12. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.30 million. During the same quarter last year, the business posted ($0.84) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts expect that Syndax Pharmaceuticals will post -3.03 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. Syndax Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $23.13.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Syndax Pharmaceuticals (SNDX) Share Price” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with's FREE daily email newsletter.